Daily grip strength response to intravenous immunoglobulin in chronic immune neuropathies

被引：14

作者：

Doneddu, Pietro E. ^{[1
]}

Hadden, Robert D. M. ^{[1
]}

机构：

[1] Kings Coll London, Dept Neurol, Kings Coll Hosp, London, England

来源：

MUSCLE & NERVE | 2020年 / 62卷 / 01期

关键词：

chronic inflammatory demyelinating polyneuropathy; CIDP; grip strength; multifocal motor neuropathy; outcome measures; DISABILITY SCALE; GUIDELINE; THERAPY; CIDP;

D O I：

10.1002/mus.26898

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction Monitoring grip strength at home may detect improvement between intravenous immunoglobulin (IVIg) treatments in patients with chronic inflammatory neuropathies (CINs). Methods Fifteen patients recorded grip strength each day, from one IVIg treatment until the next. We analyzed grip strength changes comparing thresholds of 8 kPa and 14 kPa. "Random" fluctuations of grip strength were distinguished from treatment response by smoothing the data. Results "Random" fluctuations of at least 8 kPa occurred in 27% of patients. Smoothed daily grip strength increased by at least 8 kPa above baseline in 11 (73%) patients. Grip strength increased by at least 8 kPa for 3 consecutive days in 9 (60%) patients, and 5-day block mean increased by at least 8 kPa in 10 (67%) patients. Discussion Home monitoring of grip strength confirmed treatment response in most patients with CINs on IVIg. To detect improvement in an individual patient, we suggest a threshold of at least 8 kPa on 3 consecutive days or on 5-day block mean.

引用

页码：103 / 110

页数：8

共 23 条

[1]

American Society of Hand Therapists, 1992, CLIN ASSESSMENT RECO, P43

[2] OPTIMIZING IGG THERAPY IN CHRONIC AUTOIMMUNE NEUROPATHIES: A HYPOTHESIS DRIVEN APPROACH [J].

Berger, Melvin ;

Allen, Jeffrey A. .

MUSCLE & NERVE, 2015, 51 (03) :315-326

[3] Variability in Intravenous Immunoglobulin G Regimens for Autoimmune Neuromuscular Disorders [J].

Broyles, Randy ;

Rodden, Linda ;

Riley, Patty ;

Berger, Melvin .

POSTGRADUATE MEDICINE, 2013, 125 (02) :65-72

[4] EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases [J].

Elovaara, I. ;

Apostolski, S. ;

van Doorn, P. ;

Gilhus, N. E. ;

Hietaharju, A. ;

Honkaniemi, J. ;

van Schaik, I. N. ;

Scolding, N. ;

Sorensen, P. Soelberg ;

Udd, B. .

EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (09) :893-908

[5]

IVIg Guideline Development Group of the IVIg Expert Working Group, 2012, CLIN GUID IMM US

[6] Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? [J].

Knak, Kirsten L. ;

Andersen, Linda K. ;

Christiansen, Ingelise ;

Markvardsen, Lars K. .

MUSCLE & NERVE, 2018, 58 (03) :449-452

[7] Optimization of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy Evaluated by Grip Strength Measurement [J].

Kokubun, Norito ;

Sada, Tsubasa ;

Yuki, Nobuhiro ;

Okabe, Momoka ;

Hirata, Koichi .

EUROPEAN NEUROLOGY, 2013, 70 (1-2) :65-69

[8] A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies [J].

Lunn, Michael P. ;

Ellis, Lauren ;

Hadden, Robert D. ;

Rajabally, Yusuf A. ;

Winer, John B. ;

Reilly, Mary M. .

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (01) :33-37

[9] Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance [J].

Merkies, I. S. J. ;

van Nes, S. I. ;

Hanna, K. ;

Hughes, R. A. C. ;

Deng, C. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (11) :1194-1199

[10] Connecting impairment, disability, and handicap in immune mediated polyneuropathies [J].

Merkies, ISJ ;

Schmitz, PIM ;

van der Meché, FGA ;

Samijn, JPA ;

van Doorn, PA .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (01) :99-104

← 1 2 3 →